Author: Li, Jianping ; Shen, Xiaoying ; Tomaras, Georgia D ; Breed, Matthew W ; Howe, Savannah E ; Sui, Yongjun ; Ma, Chi ; Berzofsky, Jay A ; Kramer, Josh A ; Cam, Maggie ; LaBranche, Celia C ; Meyer, Thomas J ; Dadkhah, Kimia ; Kelly, Michael C ; Miller, Christopher J ; Fennessey, Christine M ; Williams, LaTonya D ; Montefiori, David ; Keele, Brandon F ; Greten, Tim F ; Ferrari, Guido

Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical for protection against SIV/HIV (SHIV) acquisition. Here, we evaluated the efficacy of an SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded, as there was no cross-reactivity between SIV and SHIV envelope antibodies. After 8 low-dose intrarectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated efficacy, compared with 6 naive controls, suggesting protection was achieved in the absence of anti-envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity, identified mechanisms, and may provide opportunities for novel HIV vaccines or therapeutic strategy development.

30 Mar 2023·Journal of virology

The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.

Article

Author: Desrosiers, Ronald C.

The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials.

31 Jan 2022·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis

Q3 · MEDICINE

Article

Author: Ahmad, Tauseef ; Hu, Xiaoyan ; Yu, Yueyang ; Shao, Yiming ; Rashid, Abdur ; Getaneh, Yimam ; Abidi, Syed Hani ; Li, Kang ; Feng, Yi

BACKGROUNDDespite recent advances in human immunodeficiency virus-1 (HIV-1) prevention, a fast, safe, and effective vaccine will probably be necessary to end the HIV/AIDS pandemic. This study was conducted to evaluate global research trends and map the key bibliometric indices in HIV-1 genetic diversity from 1998 to 2021.METHODSA comprehensive online search was conducted in the Web of Science Core Collection database to retrieve published literature on HIV-1 genetic diversity. Key bibliometric indicators were calculated and evaluated using HistCite^TM, Bibliometrix: An R-tool, and VOSviewer software for windows.RESULTSA total of 2,060 documents written by 9,201 authors and published in 250 journals were included in the final analysis. Year 2012 was the most productive year with 121 (5.87%) publications. The most prolific author was Shao Yiming (n = 74, 3.59%) from Chinese Center for Disease Control and Prevention. The United States of America was the highly contributing and influential country (n = 681, 33.05%). AIDS Research and Human Retroviruses was the most productive journal (n = 562, 27.2%). Network visualization shows that HIV-1 was the most widely used author keyword.CONCLUSIONThis study provides global research trends and detailed information on HIV-1 genetic diversity. The amount of scientific literature on HIV-1 genetic diversity research has rapidly increased in the last two decades. The maximum number of articles on HIV-1 genetic diversity was published in developed countries; therefore, a scientific research collaboration among researchers and institutes in low-income countries should be promoted and supported.

100 Deals associated with AIDS vaccine (Medestea)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	Italy	Medestea Internazionale Srl	05 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2014	Not Applicable	HIV Infections	244	HIV vaccine (Participants with specified low-risk criteria)	tsikhrxmuj(xnmamovzen) = glkpyfzxmj ybcdkajloj (rasnfnrqed, 1.6 - 5.6)	-	01 Jan 2014
IAS2014	Not Applicable	HIV Infections	244	HIV vaccine (Participants without specified low-risk criteria)	tsikhrxmuj(xnmamovzen) = ukvlstajms ybcdkajloj (rasnfnrqed, 0.3 - 4.0)	-	01 Jan 2014
IAS2006	Not Applicable	HIV Infections	1,200	HIV vaccine (Young people (<45 years))	efssbtacnk(tqzzpfykhx) = pyibjpgfik wclpmxevds (cnfwzenrui, 1.0 - 2.8)	-	01 Jan 2006
VAX004 (IAS2006)	Not Applicable	-	37	Bivalent Glycoprotein (gp) 120 preventive HIV vaccine (High-risk uninfected women)	viunaifeag(jknsemnrqg) = giqlzjbdqi djvgfathvv (feztdhxayj, p=0.04)	-	01 Jan 2006
IAS2002	Not Applicable	Risk Reduction Behavior	-	HIV vaccine (AIDSVAX B/B)	smarqywvfp(dfzouqgbog) = kfscfwbsur gpjmilacko (czvnhejyez ) View more	-	01 Jan 2002
IAS2002	Not Applicable	Risk Reduction Behavior	-	Placebo	smarqywvfp(dfzouqgbog) = hrauzdmmre gpjmilacko (czvnhejyez ) View more	-	01 Jan 2002

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

AIDS vaccine (Medestea)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation